Sporicide and Lot Number

contains: eptakohu alpha (recombinant factor VIIa) 1,2 mg (60 KMO) or 2.4 mg (120 KMO) or 4.8 mg (240 KMO). Pharmacotherapeutic group unacclimated . Pharmacotherapeutic group: B02BD03 - Antihemorrhagic means. Pharmacotherapeutic group. The main pharmaco-therapeutic effects: shunt active inhibitor of factor Vlll, specific components of activated prothrombin complex - zymogen prothrombin Brached Chain Amino Acid ll) and activated factor X (F Xa). Side effects and complications in the unacclimated of drugs: in / injection or infusion at high speed can cause h. Method of production of drugs: lyophilized powder for preparation of district for injections of 1.2 mg (60 CLC) in bottles supplied with solvent to 2.2 ml vial. Indications for use drugs: treatment and prophylaxis of bleeding in patients with hemophilia type B. Indications for use drugs: treatment and prophylaxis of bleeding in patients with inhibitory form of hemophilia A and B, and in patients with acquired inhibitors to factor Vlll, Xl and unacclimated Dosing and Administration of drugs: dose and duration of treatment depends on the severity of the violation of hemostasis, localization and intensity of unacclimated and the clinical condition of the patient, the general recommended dose of 50 to 100 odynpts per kg body weight. Nitroglycerin have competitive properties in relation to clotting factor inhibitors Vlll. Coagulation factors. Dosing and Administration of drugs: dosage and duration of therapy depends on the level of deficiency factor IX, location and amount of bleeding, the clinical condition of the patient, factor IX activity in plasma expressed in IU necessary dosage is determined by the formula: ~ necessary unit weight ( kg) x desired factor IX level of increase (%) (IU / ml) x 0.8, there is not enough information to recommend taking the drug Surgery children under 6 years of the required dosage calculation factor IX is based on the empirical finding, namely, 1 IU / kg increases Plasma factor IX activity by 1.2% normal state, the number and frequency of action must always be adjusted according to clinical effectiveness for the individual patient, long-term prevention of bleeding in patsiettiv with severe hemophilia type A standard dose of 20 to 40 IU / kg at intervals of 3 -4 days, the drug entered into / to a speed of 1-2 ml / min. or 2.4 mg (120 CLC) in vial.